carbostyril has been researched along with Intestinal Diseases in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (23.08) | 29.6817 |
| 2010's | 9 (69.23) | 24.3611 |
| 2020's | 1 (7.69) | 2.80 |
| Authors | Studies |
|---|---|
| Bennett, C; Bowen, A; Friedman, CR; Grass, JE; Huang, JY; Kim, S; McCullough, AE; Morrison, SM | 1 |
| Cao, X; Jing, L; Mou, S; Xu, N; Yu, Z; Zhang, C | 1 |
| Houwen, RHJ; Slae, M; van der Woerd, WL; Wilschanski, M | 1 |
| Avolio, J; Garg, M; Gonska, T; Needham, B; Ooi, CY; Rossi, L; Surette, MG; Syed, SA; Young, K | 1 |
| Fujita, T; Kato, M; Katsuki, S; Kurokawa, S; Nishikawa, K; Ohira, K; Ohta, H; Saitoh, Y; Sato, Y; Yamada, M | 1 |
| Boelsterli, UA; Fujimoto, K; Lee, KK; Redinbo, MR; Saitta, KS; Zhang, C | 1 |
| Amagase, K; Satoh, H; Takeuchi, K | 1 |
| Arakawa, T; Fujimoto, K; Handa, O; Higuchi, K; Naito, Y; Sakata, Y; Shiba, M; Takeuchi, T; Tanigawa, T; Watanabe, T; Yoshikawa, T | 1 |
| Arakawa, T; Fujiwara, Y; Kamata, N; Nadatani, Y; Nagami, Y; Otani, K; Shiba, M; Shimada, S; Tanaka, F; Tanigawa, T; Tominaga, K; Watanabe, T; Yamagami, H | 1 |
| Brisou, P; Gaillard, C; Gaillard, T; Gaillot, O; Lamblin, G; Martinaud, C; Souraud, JB | 1 |
| Abe, T; Fujioka, T; Inoue, K; Kodama, M; Mizukami, K; Murakami, K; Okimoto, T; Uchida, M | 1 |
| Ando, T; Goto, H; Hirooka, Y; Itoh, A; Maeda, O; Nakamura, M; Niwa, Y; Ohmiya, N | 1 |
| Kanatsu, K; Kato, S; Mizoguchi, H; Ogawa, Y; Takeuchi, K; Tanaka, A | 1 |
2 review(s) available for carbostyril and Intestinal Diseases
| Article | Year |
|---|---|
Effects of new and emerging therapies on gastrointestinal outcomes in cystic fibrosis.
Topics: Aminophenols; Aminopyridines; Benzodioxoles; Body Mass Index; Chloride Channel Agonists; Cystic Fibrosis; Digestive System; Drug Combinations; Gastroesophageal Reflux; Humans; Hydrogen-Ion Concentration; Intestinal Diseases; Liver Diseases; Probiotics; Quinolones; Treatment Outcome; Weight Gain | 2017 |
Microbiota Plays a Key Role in Non-Steroidal Anti-Inflammatory Drug-Induced Small Intestinal Damage.
Topics: Alanine; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Gastrointestinal Microbiome; Humans; Intestinal Diseases; Intestine, Small; Probiotics; Quinolones; Ulcer | 2017 |
5 trial(s) available for carbostyril and Intestinal Diseases
| Article | Year |
|---|---|
Impact of CFTR modulation with Ivacaftor on Gut Microbiota and Intestinal Inflammation.
Topics: Adolescent; Adult; Aminophenols; Child; Child, Preschool; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Dysbiosis; Enterobacteriaceae; Female; Gastrointestinal Microbiome; Humans; Inflammation; Intestinal Diseases; Male; Middle Aged; Mutation; Quinolones | 2018 |
A randomized, double-blinded, placebo-controlled, multicenter trial, healing effect of rebamipide in patients with low-dose aspirin and/or non-steroidal anti-inflammatory drug induced small bowel injury.
Topics: Aged; Alanine; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Aspirin; Capsule Endoscopy; Dietary Proteins; Double-Blind Method; Female; Humans; Intestinal Diseases; Intestinal Mucosa; Intestine, Small; Male; Middle Aged; Quinolones; Wound Healing | 2014 |
A multicenter, randomized, double-blind, placebo-controlled trial of high-dose rebamipide treatment for low-dose aspirin-induced moderate-to-severe small intestinal damage.
Topics: Aged; Alanine; Anti-Ulcer Agents; Aspirin; Capsule Endoscopy; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Humans; Intestinal Diseases; Intestine, Small; Male; Quinolones; Severity of Illness Index; Treatment Outcome | 2015 |
Aspirin-induced small bowel injuries and the preventive effect of rebamipide.
Topics: Adult; Aged; Alanine; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Aspirin; Capsule Endoscopy; Cross-Over Studies; Double-Blind Method; Humans; Intestinal Diseases; Intestinal Mucosa; Intestine, Small; Male; Middle Aged; Omeprazole; Placebos; Quinolones; Young Adult | 2011 |
Efficacy of rebamipide for diclofenac-induced small-intestinal mucosal injuries in healthy subjects: a prospective, randomized, double-blinded, placebo-controlled, cross-over study.
Topics: Adult; Alanine; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Capsule Endoscopy; Cross-Over Studies; Diclofenac; Double-Blind Method; Female; Follow-Up Studies; Humans; Intestinal Diseases; Intestinal Mucosa; Intestine, Small; Male; Prospective Studies; Quinolones; Severity of Illness Index; Treatment Outcome | 2008 |
6 other study(ies) available for carbostyril and Intestinal Diseases
| Article | Year |
|---|---|
Quinolone nonsusceptibility among enteric pathogens isolated from international travelers - Foodborne Diseases Active Surveillance Network (FoodNet) and National Antimicrobial Monitoring System (NARMS), 10 United States sites, 2004 - 2014.
Topics: Drug Resistance, Microbial; Foodborne Diseases; History, 21st Century; Humans; Intestinal Diseases; Odds Ratio; Population Surveillance; Quinolones; Travel; Travel-Related Illness; United States | 2019 |
Protective effect and mechanism of rebamipide on NSAIDs associated small bowel injury.
Topics: Alanine; Animals; Anti-Inflammatory Agents, Non-Steroidal; Claudin-1; Cytokines; Diclofenac; Disease Models, Animal; Gene Expression Regulation; Humans; Intestinal Diseases; Intestinal Mucosa; Intestine, Small; Male; NF-kappa B; Quinolones; Rats, Sprague-Dawley; Signal Transduction; Toll-Like Receptor 4; Ulcer; Zonula Occludens-1 Protein | 2021 |
Bacterial β-glucuronidase inhibition protects mice against enteropathy induced by indomethacin, ketoprofen or diclofenac: mode of action and pharmacokinetics.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Chromatography, Liquid; Diclofenac; Enzyme Inhibitors; Glucuronidase; Hepatocytes; Indomethacin; Intestinal Diseases; Intestine, Small; Ketoprofen; Male; Mice; Mice, Inbred C57BL; Quinolones; Statistics, Nonparametric; Tandem Mass Spectrometry; Thiourea | 2014 |
Mucosal protective agents prevent exacerbation of NSAID-induced small intestinal lesions caused by antisecretory drugs in rats.
Topics: Alanine; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Diclofenac; Dose-Response Relationship, Drug; Gastric Mucins; Gastrointestinal Agents; Intestinal Diseases; Intestinal Mucosa; Intestine, Small; Male; Misoprostol; Mucus; Omeprazole; Protective Agents; Proton Pump Inhibitors; Quinolones; Ranitidine; Rats; Rats, Wistar; Sus scrofa; Triazines | 2014 |
Abdominal granuloma in a young healthy man after infection with Pasteurella multocida.
Topics: Anti-Bacterial Agents; Colectomy; Granuloma; Humans; Intestinal Diseases; Male; Pasteurella Infections; Pasteurella multocida; Quinolones; Young Adult | 2009 |
Protective effect of rebamipide on indomethacin-induced intestinal damage in rats.
Topics: Alanine; Ampicillin; Animals; Anti-Ulcer Agents; Bacterial Translocation; Catalase; Dose-Response Relationship, Drug; Enterobacteriaceae; Enzyme Inhibitors; Indomethacin; Intestinal Diseases; Lipid Peroxidation; Male; Nitric Oxide Synthase; Peroxidase; Quinolones; Rats; Rats, Sprague-Dawley; Superoxide Dismutase | 2001 |